Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ASCO 2014: news, hopes, hypes?

ASCO 2014: news, hopes, hypes? editorial memo (2014) 7:196–197 DOI 10.1007/s12254-014-0189-x Wolfgang Eisterer Received: 6 November 2014 / Accepted: 17 November 2014 / Published online: 28 November 2014 © Springer-Verlag Wien 2014 Wolfgang Eisterer This year’s American Society of Clinical Oncology (ASCO) In the treatment of locally advanced head and neck saw some major improvements in the treatment of tumors concomitant chemoradiotherapy is considered as patients with solid tumors which, however, did not lead standard of care. Owing to the fact that systemic relapse to a change in current clinical practice; at least not in the occurs frequently during follow-up in these patients treatment of those solid tumors which will be reported strategies that include systemic therapy have been devel- within this summary. Surprisingly not all the therapeutic oped. Special interest has focused on the concept of progress stems from targeted therapy but also from long- sequential therapy meaning induction chemotherapy known substances like aromatase inhibitors. In total, before chemoradiotherapy. Numerous phase III stud- more than 5000 abstracts have been presented at ASCO ies have failed to show an improvement in survival for 2014. Within this review the most important abstracts cov- induction chemotherapy [3–5]. An Italian phase III study ering head and neck http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Loading next page...
 
/lp/springer-journals/asco-2014-news-hopes-hypes-h7CNQiiMfU
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-014-0189-x
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2014) 7:196–197 DOI 10.1007/s12254-014-0189-x Wolfgang Eisterer Received: 6 November 2014 / Accepted: 17 November 2014 / Published online: 28 November 2014 © Springer-Verlag Wien 2014 Wolfgang Eisterer This year’s American Society of Clinical Oncology (ASCO) In the treatment of locally advanced head and neck saw some major improvements in the treatment of tumors concomitant chemoradiotherapy is considered as patients with solid tumors which, however, did not lead standard of care. Owing to the fact that systemic relapse to a change in current clinical practice; at least not in the occurs frequently during follow-up in these patients treatment of those solid tumors which will be reported strategies that include systemic therapy have been devel- within this summary. Surprisingly not all the therapeutic oped. Special interest has focused on the concept of progress stems from targeted therapy but also from long- sequential therapy meaning induction chemotherapy known substances like aromatase inhibitors. In total, before chemoradiotherapy. Numerous phase III stud- more than 5000 abstracts have been presented at ASCO ies have failed to show an improvement in survival for 2014. Within this review the most important abstracts cov- induction chemotherapy [3–5]. An Italian phase III study ering head and neck

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Nov 28, 2014

References